Data shows non-invasive assay effectively identifies melanoma
LA JOLLA, Calif., April 15 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, will present data at the American Association of Cancer Research on its non-invasive assay that distinguishes melanoma from benign moles. The study entitled: "A Non-invasive Genomic Assay for the Detection of Melanoma in Suspicious Pigmented Nevi", shows that the assay has 100% sensitivity and 90.6% specificity. The biomarker based on 20 target genes is being developed as part of the company's proprietary molecular-based approach that uses its EGIR(TM) (Epidermal Genetic Information Retrieval) technology to identify melanoma at the earliest stages of disease. The late breaking abstract #LB-221 will be presented at Poster Session 19 on Tuesday, April 15.
DermTech's EGIR ("tape stripping") method is based on applying a custom adhesive strip to the skin's surface to obtain RNA and subsequently using gene expression profiling techniques to identify disease.
"Results of this study suggest that the malignant melanocyte, directly or indirectly, induces an alteration in stratum corneum gene expression," said Sherman Chang, PhD, Director of Molecular Biology, DermTech. "These findings pave the way for the development of an objective assay based on genomic data -- a major advance over today's subjective method of identifying disease."
Although melanoma accounts for more than 70% of skin cancer deaths, when detected early it is considered highly curable. In current clinical practice, the detection of melanoma is based upon visual clinical cues including the "ABCDE" criteria for pigmented nevi and results of optical imaging techniques, such as dermoscopy and con-focal microscopy. However, depending upon the setting, only 1 to 10% of lesions biopsied for suspicion of melanoma are positive upon histopathologic examination. Thus, there is a substantial need for a test that enhances the ease and accuracy of melanoma detection.
Headquartered in La Jolla, California, DermTech International is
focused on the development and validation of molecular tests using
specimens obtained from the skin. The company's proprietary Epidermal
Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies
to evaluate its potential as a non-invasive diagnostic for melanoma and
other major diseases. It is also being studied in the context of tracking
treatment efficacy for a variety of dermatologic and other conditions,
including the effects of drugs on skin at the molecular level in advance of
observable clinical results. DermTech is actively pursuing research using
EGIR and its applications in the areas of melanoma, prostate cancer and
various skin disorders, such as psoriasis. For additional information visit
Copyright©2008 PR Newswire.
All rights reserved